Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis

References

• LiEKTamLSTomlinsonBLeflunomide in the treatment of rheumatoid arthritisClin Ther200426444745915189743
   PubMed Web of Science ®Google Scholar
• AlcornNSaundersSMadhokRBenefit-risk assessment of leflunomide: An appraisal of leflunomide in rheumatoid arthritis 10 years after licensingDrug Saf200932121123113419916579
   PubMed Web of Science ®Google Scholar
• BartlettRRDimitrijevicMMattarTLeflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejectionAgents Actions1991321–210212058454
   PubMedGoogle Scholar
• FoxRIMechanism of action of leflunomide in rheumatoid arthritisRheumatol Suppl1998532026
   PubMedGoogle Scholar
• Sanofi-AventisArava Data Sheet [Package insert]2009 Available from; www.medsafe.govt.nzAccessed 2010 Aug 30
   Google Scholar
• MladenovicVDomljanZRozmanBSafety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II studyArthritis Rheum19953811159516037488280
   PubMed Web of Science ®Google Scholar
• BeamanJMHackettLPLuxtonGIllettKFEffect of hemodialysis on leflunomide plasma concentrationsAnn Pharmacother2002361757711816264
   PubMed Web of Science ®Google Scholar
• SmolenJSKaldenJRScottDLEfficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study GroupLancet199935391492592669929017
   PubMed Web of Science ®Google Scholar
• PanoulasVFDouglasKMJMilionisHJSerum uric acid is independently associated with hypertension in patients with rheumatoid arthritisJ Hum Hypertens200822317718217960169
   PubMed Web of Science ®Google Scholar
• RuckemannKFairbanksLDCarreyEALeflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humansJ Biol Chem19982733421682216919705303
   PubMed Web of Science ®Google Scholar
• FoxRIHerrmannMLFrangouCGMechanism of action for leflunomide in rheumatoid arthritisClin Immunol199993319820810600330
   PubMed Web of Science ®Google Scholar
• CohenSIqbalILeflunomideInt J Clin Pract20035726
   Web of Science ®Google Scholar
• PawlikAHerczynskaMKurzawskiMSafranowKDziedziejkoVDrozdzikMThe effect of exon (19C > A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomidePharmacogenomics200910230330919207032
   PubMed Web of Science ®Google Scholar
• GrabarPBRozmanBLogarDPraprotnikSDolzanVDihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritisAnn Rheum Dis20096881367136819605743
   PubMed Web of Science ®Google Scholar
• XuXBlinderLShenJIn vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr miceJ Immunol199715911671749200452
   PubMed Web of Science ®Google Scholar
• CaoWWKaoPNAokiYXuJCShorthouseRAMorrisREA novel mechanism of action of the immunomodulatory drug, leflunomide: Augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2Transplant Proc1996286307930808962191
   PubMed Web of Science ®Google Scholar
• DimitrijevicMBartlettRRLeflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritisTransplant Proc1996286308630878962195
   PubMed Web of Science ®Google Scholar
• KraanMCde KosterBMElferinkJGPostWJBreedveldFCTakPPInhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: Findings in a prospective, randomized, double-blind clinical trial in fifteen patientsArthritis Rheum20004371488149510902750
   PubMed Web of Science ®Google Scholar
• KraanMCReeceRJBargECModulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centersArthritis Rheum20004381820183010943872
   PubMed Web of Science ®Google Scholar
• TchetverikovIKraanMCvan ElBHanemaaijerRDeGrootJHuizingaTWJLeflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patientsAnn Rheum Dis200867112813017875551
   PubMed Web of Science ®Google Scholar
• LitinskyIParanDLevartovskyDThe effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritisCytokine200633210611016487722
   PubMed Web of Science ®Google Scholar
• OsiriMSheaBRobinsonVLeflunomide for the treatment of rheumatoid arthritis: A systematic review and metaanalysisJ Rheumatol20033061182119012784387
   PubMed Web of Science ®Google Scholar
• OsiriMSheaBRobinsonVLeflunomide for treating rheumatoid arthritisCochrane Database Syst Rev20031CD00204712535423
   PubMed Web of Science ®Google Scholar
• EmeryPBreedveldFCLemmelEMA comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritisRheumatology (Oxford)200039665566510888712
   PubMed Web of Science ®Google Scholar
• StrandVCohenSSchiffMTreatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators GroupArch Intern Med1999159212542255010573044
   PubMed Web of Science ®Google Scholar
• StrandVTugwellPBombardierCFunction and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators GroupArthritis Rheum19994291870187810513801
   PubMed Web of Science ®Google Scholar
• WhittleSLHughesRAFolate supplementation and methotrexate treatment in rheumatoid arthritis: A reviewRheumatology (Oxford)200443326727114963199
   PubMed Web of Science ®Google Scholar
• PreySPaulCEffect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: A systematic reviewBr J Dermatol2009160362262818945303
   PubMed Web of Science ®Google Scholar
• van EdeAELaanRFRoodMJEffect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled studyArthritis Rheum20014471515152411465701
   PubMed Web of Science ®Google Scholar
• FransenJLaanRFJMvan Der LaarMAFJHuizingaTWJvan RielPLCMInfluence of guideline adherence on outcome in a randomised controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritisAnn Rheum Dis200463101222122615361375
   PubMed Web of Science ®Google Scholar
• DougadosMEmeryPLemmelE-MEfficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month dataJ Rheumatol200330122572257914719196
   PubMed Web of Science ®Google Scholar
• TugwellPWellsGStrandVClinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators GroupArthritis Rheum200043350651410728742
   PubMed Web of Science ®Google Scholar
• CohenSCannonGWSchiffMTwo-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator GroupArthritis Rheum20014491984199211592358
   PubMed Web of Science ®Google Scholar
• ScottDLSmolenJSKaldenJRTreatment of active rheumatoid arthritis with leflunomide: Two year follow up of a double blind, placebo controlled trial versus sulfasalazineAnn Rheum Dis2001601091392311557646
   PubMed Web of Science ®Google Scholar
• KaldenJRScottDLSmolenJSImproved functional ability in patients with rheumatoid arthritis – longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study GroupJ Rheumatol20012891983199111550964
   PubMed Web of Science ®Google Scholar
• LarsenAKvienTKSchattenkirchnerMSlowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazineScand J Rheumatol200130313514211469522
   PubMed Web of Science ®Google Scholar
• KaldenJRSchattenkirchnerMSorensenHThe efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year followup studyArthritis Rheum20034861513152012794818
   PubMed Web of Science ®Google Scholar
• US FDACDERCBERCDRHGuidance for Industry. Clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA)1999 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071579.pdfAccessed 2010 Jul 13
   Google Scholar
• FelsonDTAndersonJJBoersMAmerican College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisArthritis Rheum19953867277357779114
   PubMed Web of Science ®Google Scholar
• PinalsRSMasiATLarsenRAPreliminary criteria for clinical remission in rheumatoid arthritisArthritis Rheum19812410130813157306232
   PubMed Web of Science ®Google Scholar
• van GestelAMPrevooMLvan ‘t HofMAvan RijswijkMHvan de PutteLBvan RielPLDevelopment and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism CriteriaArthritis Rheum199639134408546736
   PubMed Web of Science ®Google Scholar
• SesinCABinghamCO3rdRemission in rheumatoid arthritis: Wishful thinking or clinical reality?Semin Arthritis Rheum200535318519616325659
   PubMed Web of Science ®Google Scholar
• van RielPKaldenJComplete remission rates with leflunomide in rheumatoid arthritis: An analysis from the leflunomide global integrated database (GIDB)Ann Rheum Dis200362Suppl 1
   Google Scholar
• SharpJTStrandVLeungHHurleyFLoew-FriedrichITreatment with leflunomide slows radiographic progression of rheumatoid arthritis: Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators GroupArthritis Rheum200043349550510728741
   PubMed Web of Science ®Google Scholar
• van der HeijdeDKaldenJScottDSmolenJStrandVLong term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 yearsAnn Rheum Dis200463673773915140783
   PubMed Web of Science ®Google Scholar
• PfeilALippoldJEidnerTEffects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysisRheumatol Int200929328729518787830
   PubMed Web of Science ®Google Scholar
• KremerJMMethotrexate and leflunomide: Biochemical basis for combination therapy in the treatment of rheumatoid arthritisSemin Arthritis Rheum1999291142610468411
   PubMed Web of Science ®Google Scholar
• WeinblattMEKremerJMCoblynJSPharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritisArthritis Rheum19994271322132810403258
   PubMed Web of Science ®Google Scholar
• KremerJMGenoveseMCCannonGWConcomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trialAnn Intern Med2002137972673312416946
   PubMed Web of Science ®Google Scholar
• KremerJGenoveseMCannonGWCombination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trialJ Rheumatol20043181521153115290730
   PubMed Web of Science ®Google Scholar
• DougadosMEmeryPLemmelEMZerbiniCAFBrinSvan RielPWhen a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?Ann Rheum Dis2005641445115271770
   PubMed Web of Science ®Google Scholar
• BreedveldFCWeismanMHKavanaughAFThe PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis Rheum2006541263716385520
   PubMed Web of Science ®Google Scholar
• KlareskogLvan der HeijdeDde JagerJPTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trialLancet2004363941067568115001324
   PubMed Web of Science ®Google Scholar
• LipskyPEvan der HeijdeDMSt ClairEWInfliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupN Engl J Med2000343221594160211096166
   PubMed Web of Science ®Google Scholar
• WeinblattMEKeystoneECFurstDEAdalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis Rheum2003481354512528101
   PubMed Web of Science ®Google Scholar
• FinckhASimardJFDuryeaJThe effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: A population-based studyArthritis Rheum2006541545916385495
   PubMed Web of Science ®Google Scholar
• KristensenLESaxneTNilssonJAGeborekPImpact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern SwedenArthritis Res Ther200686R17417121678
   PubMed Web of Science ®Google Scholar
• ZinkAListingJKarySTreatment continuation in patients receiving biological agents or conventional DMARD therapyAnn Rheum Dis20056491274127915708884
   PubMed Web of Science ®Google Scholar
• CombeBCodreanuCFioccoUEtanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: A double-blind comparisonAnn Rheum Dis200665101357136216606651
   PubMed Web of Science ®Google Scholar
• O’DellJRPetersenKLeffREtanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritisJ Rheumatol200633221321816358366
   PubMed Web of Science ®Google Scholar
• FurstDESchiffMHFleischmannRMAdalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)J Rheumatol200330122563257114719195
   PubMed Web of Science ®Google Scholar
• BurmesterGRMarietteXMontecuccoCAdalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trialAnn Rheum Dis200766673273917329305
   PubMed Web of Science ®Google Scholar
• KaldenJRAntoniCAlvaro-GraciaJMUse of combination of leflunomide with biological agents in treatment of rheumatoid arthritisJ Rheumatol20053281620163116078347
   PubMed Web of Science ®Google Scholar
• BinghamSJBuchMHKerrMAEmeryPValadao BarcelosATInduction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomideArthritis Rheum200450124072407315593202
   PubMed Web of Science ®Google Scholar
• IbanezTCTayelYMCriadoBASanzHAMolaMESafety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritisRheumatology (Oxford)200544111467146816174647
   PubMed Web of Science ®Google Scholar
• FlendrieMCreemersMCWWelsingPMJvan RielPLCMThe influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational studyRheumatology (Oxford)200544447247815598707
   PubMed Web of Science ®Google Scholar
• GodinhoFGodfrinBEl MahouSNavauxFZabranieckiLCantagrelASafety of leflunomide plus infliximab combination therapy in rheumatoid arthritisClin Exp Rheumatol200422332833015144127
   PubMed Web of Science ®Google Scholar
• HansenKECushJSinghalAThe safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritisArthritis Rheum200451222823215077264
   PubMed Web of Science ®Google Scholar
• KaldenJRNussleinHGWollenhauptJBurmesterGRKrugerKAntoniCCombination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: Safety and efficacy in an open-label clinical trialClin Exp Rheumatol200826583484019032816
   PubMed Web of Science ®Google Scholar
• NordstromDCKonttinenLKorpelaMClassic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experienceRheumatol Int200626874174816205925
   PubMed Web of Science ®Google Scholar
• Ortiz GarciaAMGonzalez-AlvaroIPardoRREffectiveness and safety of infliximab combined with leflunomide in chronic polyarthritisClin Exp Rheumatol200422679015638063
   PubMed Web of Science ®Google Scholar
• PerdrigerAMarietteXKuntzJLSafety of infliximab used in combination with leflunomide or azathioprine in daily clinical practiceJ Rheumatol200633586586916652418
   PubMed Web of Science ®Google Scholar
• KielyPDWJohnsonDMInfliximab and leflunomide combination therapy in rheumatoid arthritis: An open-label studyRheumatology (Oxford)200241663163712048288
   PubMed Web of Science ®Google Scholar
• FinckhADehlerSGabayCDoctorsSThe effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: A population-based studyAnn Rheum Dis2009681333918230627
   PubMed Web of Science ®Google Scholar
• StrangfeldAHierseFKekowJComparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomideAnn Rheum Dis200968121856186219126559
   PubMed Web of Science ®Google Scholar
• de StefanoRFratiENargiFComparison of combination therapies in the treatment of rheumatoid arthritis: Leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alphaClin Rheumatol201029551752420082236
   PubMed Web of Science ®Google Scholar
• GoldsmithCHBoersMBombardierCTugwellPCriteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT CommitteeJ Rheumatol19932035615658478874
   PubMed Web of Science ®Google Scholar
• HenesJCSchedelJKanzLKoetterIRituximab and concomitant leflunomide for the treatment of rheumatoid arthritisRheumatol Int201030570971220012622
   PubMed Web of Science ®Google Scholar
• GabayCChatzidionysiouKNasonovEEffectiveness of different DMARD co-therapies in rituximab-treated rheumatoid arthritis (RA) patients – results of a one-year follow up study from the Cerrera collaborationAnn Rheum Dis201069S3120007619
   PubMed Web of Science ®Google Scholar
• KaranikolasGCharalambopoulosDVaiopoulosGAdjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: A 48-week, comparative, prospective studyRheumatology (Oxford)20084791384138818603660
   PubMed Web of Science ®Google Scholar
• BotsiosCSfrisoPFurlanAAnakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritisReumatismo20075913237 Italian17435840
   PubMedGoogle Scholar
• KaltwasserJPNashPGladmanDEfficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trialArthritis Rheum20045061939195015188371
   PubMed Web of Science ®Google Scholar
• NashPThaciDBehrensFFalkFKaltwasserJPLeflunomide improves psoriasis in patients with psoriatic arthritis: An in-depth analysis of data from the TOPAS studyDermatology2006212323824916549920
   PubMed Web of Science ®Google Scholar
• MalesciDTirriRBuonoRLa MontagnaGLeflunomide in psoriatic arthritis: A retrospective study of discontinuation rate in daily clinical practice compared with methotrexateClin Exp Rheumatol200725688188418173924
   PubMed Web of Science ®Google Scholar
• SilvermanESpiegelLHawkinsDLong-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritisArthritis Rheum200552255456215693001
   PubMed Web of Science ®Google Scholar
• SilvermanEMouyRSpiegelLLeflunomide or methotrexate for juvenile rheumatoid arthritisN Engl J Med2005352161655166615843668
   PubMed Web of Science ®Google Scholar
• RemerCFWeismanMHWallaceDJBenefits of leflunomide in systemic lupus erythematosus: A pilot observational studyLupus200110748048311480845
   PubMed Web of Science ®Google Scholar
• TamLSLiEKWongCKLamCWKSzetoCCDouble-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosusLupus200413860160415462490
   PubMed Web of Science ®Google Scholar
• van WoerkomJMKruizeAAGeenenRSafety and efficacy of leflunomide in primary Sjögren’s syndrome: A phase II pilot studyAnn Rheum Dis20076681026103217223657
   PubMed Web of Science ®Google Scholar
• HaibelHRudwaleitMBraunJSieperJSix months open label trial of leflunomide in active ankylosing spondylitisAnn Rheum Dis200564112412615608310
   PubMed Web of Science ®Google Scholar
• van DenderenJCvan der PaardtMNurmohamedMTde RyckYMMADijkmansBACvan der Horst-BruinsmaIEDouble blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitisAnn Rheum Dis200564121761176415901634
   PubMed Web of Science ®Google Scholar
• BoswellJSCostnerMILeflunomide as adjuvant treatment of dermatomyositisJ Am Acad Dermatol200858340340618194823
   PubMed Web of Science ®Google Scholar
• BremerJPUllrichSLaudienMGrossWLLamprechtPMethotrexate plus leflunomide for the treatment of relapsingWegener’s granulomatosis. A retrospective uncontrolled studyClin Exp Rheumatol2010281 Suppl 57677120412706
   PubMed Web of Science ®Google Scholar
• MetzlerCMiehleNMangerKElevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosisRheumatology (Oxford)20074671087109117519271
   PubMed Web of Science ®Google Scholar
• SuissaSErnstPHudsonMBittonAKezouhANewer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritisAm J Med20041172879215234643
   PubMed Web of Science ®Google Scholar
• van RoonENJansenTLTAHoutmanNMSpoelstraPBrouwersJRBJLeflunomide for the treatment of rheumatoid arthritis in clinical practice: Incidence and severity of hepatotoxicityDrug Saf200427534535215061688
   PubMed Web of Science ®Google Scholar
• CurtisJRBeukelmanTOnofreiAElevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomideAnn Rheum Dis2010691434719147616
   PubMed Web of Science ®Google Scholar
• USFDADrug and Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide) Available from; http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm218679.htm#data_summaryAccessed 2010 Jul 13
   Google Scholar
• SaagKGTengGGPatkarNMAmerican College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisArthritis Rheum200859676288418512708
   PubMed Web of Science ®Google Scholar
• SawadaTInokumaSSatoTLeflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritisRheumatology (Oxford)20094891069107219321513
   PubMed Web of Science ®Google Scholar
• SatoTInokumaSSagawaAFactors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritisRheumatology (Oxford)200948101265126819651883
   PubMed Web of Science ®Google Scholar
• SuissaSHudsonMErnstPLeflunomide use and the risk of interstitial lung disease in rheumatoid arthritisArthritis Rheum20065451435143916645972
   PubMed Web of Science ®Google Scholar
• ChikuraBLaneSDawsonJKClinical expression of leflunomide-induced pneumonitisRheumatology (Oxford)20094891065106819321511
   PubMed Web of Science ®Google Scholar
• HorvathIFSzantoACsikiZSzodorayPZeherMIntrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomidePathol Oncol Res200814110110418392955
   PubMed Web of Science ®Google Scholar
• RozinAYiglaMGuralnikLRheumatoid lung nodulosis and osteopathy associated with leflunomide therapyClin Rheumatol200625338438816211338
   PubMed Web of Science ®Google Scholar
• PanoulasVFMetsiosGSPaceAVHypertension in rheumatoid arthritisRheumatology (Oxford)20084791286129818467370
   PubMed Web of Science ®Google Scholar
• RozmanBPraprotnikSLogarDLeflunomide and hypertensionAnn Rheum Dis200261656756912006342
   PubMed Web of Science ®Google Scholar
• BharadwajAHaroonNPeripheral neuropathy in patients on leflunomideRheumatology (Oxford)2004437934
   Web of Science ®Google Scholar
• CarulliMTDaviesUMPeripheral neuropathy: An unwanted effect of leflunomide?Rheumatology (Oxford)200241895295312154221
   PubMed Web of Science ®Google Scholar
• KhoLKKermodeAGLeflunomide-induced peripheral neuropathyJ Clin Neurosci200714217918117107800
   PubMed Web of Science ®Google Scholar
• van RielPLCMSmolenJSEmeryPLeflunomide: A manageable safety profileJ Rheumatol Suppl20047121415170904
   PubMedGoogle Scholar
• MetzlerCArltACGrossWLBrandtJPeripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomideAnn Rheum Dis200564121798180016284351
   PubMed Web of Science ®Google Scholar
• BonnelRAGrahamDJPeripheral neuropathy in patients treated with leflunomideClin Pharmacol Ther200475658058515179412
   PubMed Web of Science ®Google Scholar
• MartinKBentaberryFDumoulinCPeripheral neuropathy associated with leflunomide: Is there a risk patient profile?Pharmacoepidemiol Drug Saf2007161747816845649
   PubMed Web of Science ®Google Scholar
• RichardsBLSpiesJMcGillNEffect of leflunomide on the peripheral nerves in rheumatoid arthritisIntern Med J200737210110717229252
   PubMed Web of Science ®Google Scholar
• CoblynJSShadickNHelfgottSLeflunomide-associated weight loss in rheumatoid arthritisArthritis Rheum20014451048105111352235
   PubMed Web of Science ®Google Scholar
• BerkowitzDMBecharaRIWolfendenLLAn unusual cause of cough and dyspnea in an immunocompromised patientChest200713151599160217494814
   PubMed Web of Science ®Google Scholar
• UlusoyHBilgiciAKuruOCelenkCPulmonary abscess due to leflunomide use in rheumatoid arthritis: A case reportRheumatol Int200525213914215322813
   PubMed Web of Science ®Google Scholar
• BruynGAWJansenTLTen BrinkeAde VriesMHoutmanPMvan RoonENCavitating pneumonia, a severe complication of leflunomide therapy in chronic polyarthritisRheumatology (Oxford)200746355355417132691
   PubMed Web of Science ®Google Scholar
• UrugaHIzumiSHojoMA patient with Mycobacterium avium lung disease presenting with rapid, progressive and multiple cavity formation, who had been treated rheumatoid arthritis with disease modifying anti-rheumatic drugs (DMARDs)Nihon Kokyuki Gakkai Zasshi2008463195201 Japanese18409565
   PubMedGoogle Scholar
• HocevarARozmanBPraprotnikSLeflunomide-associated tuberculosis?Rheumatology (Oxford)200645222822916319103
   PubMed Web of Science ®Google Scholar
• AgrawalSSharmaADual mycobacterial infection in the setting of leflunomide treatment for rheumatoid arthritisAnn Rheum Dis200766227717242021
   PubMed Web of Science ®Google Scholar
• DelankKSHansenTEyselPEckardtAInfections of the musculoskeletal system with chronic polyarthritis during a combination therapy with Methotrexate and LeflunomideZ Orthop Ihre Grenzgeb20021405555560 German12226783
   PubMed Web of Science ®Google Scholar
• GroverRDhirVAnejaRSevere infections following leflunomide therapy for rheumatoid arthritisRheumatology (Oxford)200645791892016717066
   PubMed Web of Science ®Google Scholar
• JenksKAStampLKO’DonnellJLSavageRLChapmanPTLeflunomide-associated infections in rheumatoid arthritisJ Rheumatol200734112201220317937473
   PubMed Web of Science ®Google Scholar
• TerakiYHitomiKSatoYHamamatsuYIzakiSLeflunomide-induced toxic epidermal necrolysisInt J Dermatol200645111370137117076730
   PubMed Web of Science ®Google Scholar
• PieringerHStubyUBiesenbachGPatients with rheumatoid arthritis undergoing surgery: How should we deal with antirheumatic treatment?Sem Arthritis Rheum2007365278286
   PubMed Web of Science ®Google Scholar
• FuerstMMohlHBaumgartelKRutherWLeflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgeryRheumatol Int200626121138114216736164
   PubMed Web of Science ®Google Scholar
• TanakaNSakahashiHSatoEHiroseKIshimaTIshiiSExamination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritisJ Clin Rheumatol20039211511817041441
   PubMed Web of Science ®Google Scholar
• WolfeFMichaudKStephensonBDoyleJToward a definition and method of assessment of treatment failure and treatment effectiveness: The case of leflunomide versus methotrexateJ Rheumatol20033081725173212913927
   PubMed Web of Science ®Google Scholar
• PisoniLMurgoAParesceEZeniSFantiniFEffectiveness and safety of leflunomide in the clinical practice. A different experienceClin Exp Rheumatol2007251115 author reply 11617418002
   PubMed Web of Science ®Google Scholar
• AletahaDStammTKapralTSurvival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: A matched observational studyAnn Rheum Dis2003621094495112972472
   PubMed Web of Science ®Google Scholar
• MartinKBentaberryFDumoulinCEffectiveness and safety profile of leflunomide in rheumatoid arthritis: Actual practice compared with clinical trialsClin Exp Rheumatol2005231808415789891
   PubMed Web of Science ®Google Scholar
• SivaCEisenSAShepherdRLeflunomide use during the first 33 months after food and drug administration approval: Experience with a national cohort of 3,325 patientsArthritis Rheum200349674575114673959
   PubMed Web of Science ®Google Scholar
• van RoonENHoekstraMTobiHLeflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuationBr J Clin Pharmacol200560331932516120072
   PubMed Web of Science ®Google Scholar
• van RoonENJansenTLTAMouradLLeflunomide in active rheumatoid arthritis: A prospective study in daily practiceBr J Clin Pharmacol200457679079715151525
   PubMed Web of Science ®Google Scholar
• WhiteDHNLynskeyNVJonesPBBLeflunomide use in New Zealand. A national prospective post-marketing studyIntern Med J20093929510219220542
   PubMed Web of Science ®Google Scholar
• AliverniniSMazzottaDZoliAFerraccioliGLeflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: Retrospective analysis of safety and adherence to treatmentDrugs Aging200926539540219552491
   PubMed Web of Science ®Google Scholar
• KellnerHBornholdtKHeinGLeflunomide in the treatment of patients with early rheumatoid arthritis–results of a prospective non-interventional studyClin Rheumatol201029891392020496042
   PubMed Web of Science ®Google Scholar
• LeeSSParkYWParkJJCombination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritisScand J Rheumatol2009381111419191187
   PubMed Web of Science ®Google Scholar
• PoorGStrandVLeflunomide Multinational StudyGEfficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: Multinational double-blind, randomized trialRheumatology (Oxford)200443674474915026583
   PubMed Web of Science ®Google Scholar
• ChambersCDJohnsonDLRobinsonLKBirth outcomes in women who have taken leflunomide during pregnancyArthritis Rheum20106251494150320131283
   PubMed Web of Science ®Google Scholar
• StrandVScottDLEmeryPPhysical function and health related quality of life: Analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritisJ Rheumatol200532459060115801012
   PubMed Web of Science ®Google Scholar